cbdMD (YCBD) Non-Current Debt (2017 - 2024)
cbdMD (YCBD) reported Non-Current Debt of $1.0 million for Q3 2024, up 11476666.67% on a YoY basis from N/an in Q4 2023, and down 4.09% sequentially from $1.1 million in Q2 2024.
cbdMD (YCBD) Non-Current Debt (2017 - 2024) Analysis & Trends
cbdMD (YCBD) has 8 years of Non-Current Debt data on file, last reported at $1.0 million in Q3 2024.
- For the quarter ending Q3 2024, Non-Current Debt rose 11476666.67% year-over-year to $1.0 million; the trailing twelve-month figure through Sep 2024 stood at $1.0 million (up 11476666.67% YoY), and the FY2024 full-year result was $1.0 million, up 11476666.67% from the prior year.
- Non-Current Debt fell to $1.0 million in Q3 2024, from $1.1 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.5 million in Q1 2024 to a low of $9.0 in Q3 2023.
- A 5-year average of $351158.8 and a median of $133582.0 in 2021 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt sank 99.99% in 2023 and jumped 11476666.67% in 2024, its largest moves.
- Tracing YCBD's Non-Current Debt over 5 years: stood at $516274.0 in 2020, then tumbled by 81.89% to $93489.0 in 2021, then surged by 34.23% to $125491.0 in 2022, then slumped by 99.99% to $9.0 in 2023, then jumped by 11476666.67% to $1.0 million in 2024.
- Business Quant data shows YCBD's Non-Current Debt at $1.0 million in Q3 2024, $1.1 million in Q2 2024, and $1.5 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | cbdMD | 438,678.80 | -2.95 Mn | 3.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Sep 30, 2023 | 9.00 |
| Jun 30, 2023 | 819.00 |
| Sep 30, 2022 | 125,491.00 |
| Jun 30, 2022 | 127,949.00 |
| Mar 31, 2022 | 77,732.00 |
| Dec 31, 2021 | 93,489.00 |
| Sep 30, 2021 | 108,985.00 |
| Jun 30, 2021 | 124,226.00 |
| Mar 31, 2021 | 139,215.00 |
| Dec 31, 2020 | 516,274.00 |
| Sep 30, 2020 | 264,367.00 |
| Jun 30, 2020 | 182,714.00 |
| Mar 31, 2020 | 205,732.00 |
| Dec 31, 2019 | 182,975.00 |
| Mar 31, 2019 | 184,300.00 |
| Dec 31, 2018 | 184,300.00 |
| Mar 31, 2018 | 328,989.00 |